东亚药业 (605177)

Zhejiang East-Asia Pharmaceutical Co., Ltd.

ASH

Tags

Chemical PharmaceuticalsPharmaceutical ManufacturingPharmaceuticals and HealthcareSynthetic BiologyContains Convertible BondsMicro Cap StocksBelow IPO Price

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 11472.60
  • Circulating A-Shares(W): 11258.39
  • Earnings Per Share(RMB): -0.6300
  • Net Assets Per Share(RMB): 14.8170
  • Operating Revenue(W RMB): 59633.89
  • Total Profit(W RMB): -8140.30
  • **Net Profit Attributable to Parent(W RMB) **: -7240.96
  • Net Profit Growth Rate(%): -260.31
  • Weighted Return on Equity(%): -3.9300
  • Operating Cash Flow Per Share(RMB): -2.2030
  • Undistributed Profit Per Share(RMB): 3.7798
  • Capital Reserve Per Share(RMB): 9.8237

2. Main Business

The main business covers:

  • Research, development, production, and sales of chemical pharmaceutical raw materials and pharmaceutical intermediates.

3. Company Basic Information

  • Company Name: Zhejiang East-Asia Pharmaceutical Co., Ltd.
  • Listing Date: 2020-11-25
  • Industry: Pharmaceutical Manufacturing
  • Address: Yanhai Industrial City, Pubagang Town, Sanmen County, Taizhou City, Zhejiang Province
  • Website: https://www.eapharm.cn/
  • Company Profile: The company is primarily engaged in the research, development, production, and sales of chemical pharmaceutical raw materials and pharmaceutical intermediates. Its leading products cover antibacterial drugs (β-lactams and quinolones), anticholinergic and synthetic antispasmodic drugs (Trimebutine Maleate), topical antifungal drugs, and other therapeutic areas. It possesses a provincial-level technology center and a provincial-level R&D center, with multiple synthesis processes granted national invention patents. Leveraging its product advantages, the company has established stable strategic partnerships with several renowned domestic and international pharmaceutical enterprises. Since its establishment, the company's main business has remained unchanged. Currently, its main products include: Cefaclor intermediates, Cefaclor active pharmaceutical ingredients (APIs), Latamoxef Sodium intermediates, Cefmetazole Sodium intermediates, Ceftizoxime Sodium intermediates, Trimebutine Maleate APIs, Levofloxacin APIs, Ofloxacin APIs, Ketoconazole APIs, etc. The company operates three production bases for APIs and pharmaceutical intermediates located in Sanmen County, Taizhou City, Zhejiang Province (East-Asia Pharmaceutical), Linhai City, Zhejiang Province (Dongbang Pharmaceutical), and Pengze County, Jiangxi Province (Jiangxi Shanyuan).

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Taizhou Ruikang Investment Partnership (Limited Partnership) Corporate Entity 250.00 2.22
2 Noah Multi-Strategy Hybrid Securities Investment Fund Class A Fund 81.17 0.72

5. Concept Sectors

  • Convertible Bonds
  • Synthetic Biology
  • Micro-cap Stocks
  • Consecutive Losses
  • Below IPO Price

Remarks

  • Data update date: 2025-10-30
  • Data source: Public Market Information